HRS-7058

HRS-7058 is a novel, highly selective small molecule inhibitor targeting the KRAS G12C mutation. It is being developed primarily for the treatment of advanced solid tumors harboring KRAS G12C mutations. The drug acts by inhibiting both active and inactive forms of the KRAS G12C protein, thereby blocking downstream oncogenic signaling pathways that drive tumor growth. HRS-7058 is administered orally and has shown promise in early-phase clinical trials for patients with advanced or metastatic solid tumors. The developer and sponsor of this drug is Shandong Suncadia Medicine, a subsidiary of Jiangsu HengRui[1][2][4][6].